On May 17, 2016, the PTAB instituted IPR proceedings on claims 1-5 of U.S. Patent No. 8,889,135, drawn to a method of treating a rheumatoid arthritis patient with a TNFα-inhibitor. Humira®, marketed by Abbvie, is allegedly covered by the claims of the ’135 patent. The IPR petition was filed by Coherus Biosciences, Inc. and asserts invalidity of the patent claims on grounds of obviousness. BMW will continue to keep you updated on developments in IPR2016-00172.
